Astria Therapeutics, Inc. (ATXS) Stock Analysis
DELISTED 2026
What happened to Astria Therapeutics, Inc. (ATXS) stock?
Astria Therapeutics, Inc. (ATXS) no longer trades on public markets. It was delisted in January 2026. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- January 2026
- Last recorded price (historical):
- $12.58 (last quote on record before the January 2026 delisting; historical, not a current quote)
Market cap $718M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Astria Therapeutics, Inc. (ATXS). Astria Therapeutics, Inc. is a biopharmaceutical company focused on rare allergic and immunological diseases. Their lead product, STAR-0215, is in preclinical development for hereditary angioedema.
Last analyzed: May 8, 2026These figures come from statements filed 13 months ago — the most recent this company has published.
Astria Therapeutics, Inc. (ATXS) Healthcare & Pipeline Overview
More about this archive record
Can I still buy ATXS shares?
No. ATXS stopped trading on public markets in January 2026, so the shares are not available through a broker. Anything you see quoted for ATXS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ATXS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Astria Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.